fda removes semaglutide from drug shortage list february 2025 The Wins. The OFA Loses. And Is Off the for Good Alert: FDA Removes Semaglutide from – FDA ends semaglutide shortage, closing

As the ANDA applicant, Apotex remains focused on advancing high-quality, affordable peptide therapies for patients

Weight loss results become clearly visible, with cumulative loss averaging 8-10% by week 12

Patients who reinitiated therapy after discontinuation were censored

Adverse events leading to dose reduction: 18.5% vs 12.4% Adverse events leading to permanent discontinuation: 5.4% vs 4.0% As a reminder, these are people who signed up to be in a trial of weight loss medications, they went through an informed consent process and they are, in theory, quite motivated and 4-5% permanently discontinued the medication because of adverse events and 12-18.5% reduced their dose and thats just in 72 weeks